Myelosuprese Léčba přípravkem Tasigna je doprovázena (National Cancer Institute Common Toxicity Criteria stupeň 3- 4) trombocytopenií, neutropenií a anemií.
Myelosuppression Treatment with Tasigna is associated with (National Cancer Institute Common Toxicity Criteria grade 3-4) thrombocytopenia, neutropenia and anaemia.